Skip to main content

RAD December 2022 Abstracts and Posters

All accepted abstracts have been published in The British Journal of Dermatology, Volume 188, Issue Supplement 2, February 2023. You may access the publication at:

#285 - Performance Metrics of a Soft Wearable Acoustomechanic Sensor for Measuring Itch in Children and Adults with Atopic Dermatitis

Albert F. Yang MD, Keum San Chun PhD, Soham R. Patel BS, Shuai Xu MD

#286 - Phase 2 Proof-of-Concept Trial in Progress— Lirentelimab in Adults with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments

Cristian Rodriguez MD, Anesa Moyer, Alan T. Chang, Enoch Bortey PhD, and Craig Paterson MD

#287- Targeting the Inhibitory Receptor Siglec-8 on Mast Cells Represents an Attractive Approach to Reduce MRGPRX2-Mediated Mast Cell Activation

Zachary Benet, Alan Wong, Julia Schanin and Bradford A. Youngblood

#288 - Once-daily crisaborole as a long-term maintenance treatment in patients with mild-to-moderate atopic dermatitis: A 52-week clinical trial

Richard Gower, JinHua Xu, Maryam S. Alam, John C. Su, Daniela E. Myers, Paul Sanders, Bonnie Vlahos, Chuanbo Zang, Jar Lan, John Werth

#301 - Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: 4-week maximal use trial

Amy Paller, Adelaide A. Hebert, John E. Jett, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli

#305 - Augmented Reality Supported Medication Adherence for Patients with Atopic Dermatitis and Psoriasis

Yannick R. Deiss, Safak Korkut, Terry Inglese, Emanuele Laurenzi

#307 - The Study Design of a Trial of Dupilumab in Adult Patients With Bullous Pemphigoid (BP): LIBERTY-BP ADEPT

Dedee F. Murrell, Pascal Joly, Victoria P. Werth, Elizabeth Laws, Leda P. Mannent, Bethany Beazley, Ariane Dubost-Brama, Arsalan Shabbir

#308 - Tralokinumab provides other clinically meaningful improvements in adolescents with moderate-to-severe atopic dermatitis who did not achieve IGA 0/1 at Week 16

Amy Paller, Andrew Blauvelt, Weily Soong, Chih-ho Hong, Marie L.A. Schuttelaar, Shannon Schneider, Marie Holst Moerch, Eric Simpson

#309 - Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest

Kristian Reich, Eric Simpson, Richard Langley, Richard B Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein De Bruin Weller, and Andrew Blauvelt

#313 - Assessment of racial differences of atopic dermatitis characteristics in a diverse outpatient cohort in the United States

Eric Sanfilippo, BS, Sneha Iyer, BS, Nisha Patel, BS, Jonathan I. Silverberg, MD, PhD, MPH

Page 1 of 5
Results 1 - 10 of 50